Skip to Main Content

Advertisement intended for health care professionals

American Society of Hematology Logo Open Menu
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 2, Issue 4
November 2025
In Progress
Blood Neoplasia Cover Image for Volume 2, Issue 4

Volume 2 Issue 4 | Blood Neoplasia | American Society of Hematology

CLINICAL TRIALS AND OBSERVATIONS

Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study
Clinical Trials & Observations
Mrinal M. Patnaik,Haris Ali,Eunice S. Wang,Abdulraheem Yacoub,James M. Foran,Vikas Gupta,Gary J. Schiller,Don Ambrose Stevens,Moshe Talpaz,Sarah Wall,Terra L. Lasho,Abhishek A. Mangaonkar,Talha Badar,Ross Lindsay,Antonio Galleu,Ira Gupta,Naveen Pemmaraju,Guillermo Garcia-Manero
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplemental data
Minimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma
Clinical Trials & Observations
Tadeusz Kubicki,Benjamin A. Derman,Jennifer H. Cooperrider,Anna Puła,David Barnidge,Dominik Dytfeld,Ken Jiang,Andrzej J. Jakubowiak
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplemental data
A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia
Clinical Trials & Observations
Ahmed Aribi,Gabriel N. Mannis,Yazan F. Madanat,Brian A. Jonas,Neil Dunavin,Gail J. Roboz,Deepa Jeyakumar,Guillermo Garcia-Manero,Hongtao Liu,Hetty E. Carraway,Jennifer N. Saultz,William Blum,Gary Schiller,Tao Huang,Paul Woodard,Barbara Klencke,X. Charlene Liao,Hong Xiang,Daniel A. Pollyea,Courtney D. DiNardo
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplemental data

MYELOID NEOPLASIA

Targeting scavenger receptor class B type 1 with a bioinspired ligand induces apoptosis or ferroptosis in AML
Adam Y. Lin,Jonathan S. Rink,Eva Yang,Sara Small,Jessica J. Gerber,Taylor J. Zak,Jessica Altman,Yasmin Abaza,Leonidas C. Platanias,Leo I. Gordon,C. Shad Thaxton
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplemental data
V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML
Vinod A. Pullarkat,Mark Levis,James McCloskey,Gabriel N. Mannis,Stephen A. Strickland,Amir T. Fathi,Tara L. Lin,Vijaya R. Bhatt,Thuva Vanniyasingam,Divya Chakravarthy,Yana Lutska,Stefan Faderl,Ronald S. Cheung,Harry P. Erba
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplemental data
Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML
Andrew D Zale,Venkata Preetam Sandeep Kaduluri,Jonathan A Webster,Mark J Levis,Ivana Gojo,Amy E DeZern,Gabriel Ghiaur,Lukasz P Gondek,William Brian Dalton,Theodoros Karantanos,Tania Jain,Gabrielle T Prince,Richard J Jones,B. Douglas Smith,Alexander J Ambinder
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplemental data
Juvenile myelomonocytic leukemia stem cells are sensitive to NK cell–mediated lysis and express targetable antigens
Shannalee Martinez,Vladimir V. Senyukov,Suheyla Hasgur,Arianexys Aquino-López,Peter D. Emanuel,Y. Lucy Liu,Elliot Stieglitz,Gregory Behbehani,Amanda R. Campbell,Dean A. Lee
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplemental data

RESEARCH LETTER

Posttranscriptional activity of eIF4E contributes to HoxA9-driven leukemogenesis
Fang Zhou,Biljana Culjkovic-Kraljacic,Christian Bach,Li Feng,Yuta Mishima,Katherine L. B. Borden,Daniel G. Tenen
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplemental data
Do all patients with chronic phase CML require a diagnostic bone marrow biopsy in the modern TKI era?
Noel F. T. Fong,David M. Ross,David T. Yeung,Timothy P. Hughes,Naranie Shanmuganathan
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Deferring treatment in hairy cell leukemia: is active surveillance safe?
Victoria M. Rogness,Xuefei Jia,Wei Wei,Brian T. Hill
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Three-year follow-up of low-dose, early-start gilteritinib maintenance in posttransplant patients with R/R FLT3mut AML
Clinical Trials & Observations
Toshiki Terao,Ken-ichi Matsuoka,Takumi Kondo,Yoshinobu Maeda
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Lymphoid Neoplasia

Targeting CDK9 inhibits the growth of KMT2A-rearranged infant leukemia and demonstrates synergy with menin inhibition
Ritul Sharma,Chunfen Zhang,Ravi Shah,Melanie M. Frigault,Amy J. Johnson,David Spencer Mangum,Luke D. Maese,Norman J. Lacayo,Aru Narendran
View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplemental data
All Issues

Advertisement intended for health care professionals

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2025 by American Society of Hematology
 

Advertisement intended for health care professionals

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals